DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Nimotuzumab is an investigational drug.
There have been 82 clinical trials for Nimotuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2016.
The most common disease conditions in clinical trials are Carcinoma, Esophageal Neoplasms, and Carcinoma, Squamous Cell. The leading clinical trial sponsors are Biotech Pharmaceutical Co., Ltd., Sun Yat-sen University, and Chinese Academy of Medical Sciences.
There are eighty-six US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Nimotuzumab
|Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer||Hui Bu||Phase 2|
|Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma||Peking University Third Hospital||N/A|
|Nimotuzumab in Combined With Concurrent Radiochemotherapy in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Children||Biotech Pharmaceutical Co., Ltd.||Phase 2|
Top disease conditions for Nimotuzumab
Top clinical trial sponsors for Nimotuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Nimotuzumab||Get Started for $10||Binding molecules specific for HER3 and uses thereof||MEDIMMUNE, LLC (Gaithersburg, MD)||Get Started for $10|
|Nimotuzumab||Get Started for $10||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||Get Started for $10|
|Nimotuzumab||Get Started for $10||Anti-EGFR activatable antibodies||CytomX Therapeutics, Inc. (South San Francisco, CA)||Get Started for $10|
|Nimotuzumab||Get Started for $10||Substituted urea derivatives and pharmaceutical uses thereof||SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)||Get Started for $10|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Nimotuzumab||Australia||AU2012340766||2031-11-23||Get Started for $10|
|Nimotuzumab||Brazil||BR112014012539||2031-11-23||Get Started for $10|
|Nimotuzumab||Canada||CA2856297||2031-11-23||Get Started for $10|
|Nimotuzumab||China||CN104093743||2031-11-23||Get Started for $10|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|